183 related articles for article (PubMed ID: 37102209)
1. Rapidly progressing generalized bullous fixed drug eruption after the first dose of COVID-19 messenger RNA vaccination.
Choi S; Kim SH; Hwang JH; Jang HW; Oh SH; Kim DY; Kim TG
J Dermatol; 2023 Sep; 50(9):1190-1193. PubMed ID: 37102209
[TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
[TBL] [Abstract][Full Text] [Related]
3. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.
Kong J; Cuevas-Castillo F; Nassar M; Lei CM; Idrees Z; Fix WC; Halverstam C; Mir A; Elbendary A; Mathew A
J Infect Public Health; 2021 Oct; 14(10):1392-1394. PubMed ID: 34294590
[TBL] [Abstract][Full Text] [Related]
4. Generalized Papulovesicular Eruption as a Side Effect of the Pfizer-BioNTech COVID-19 Vaccine.
Alamri A; Alghamdi Y; Alamri SJ; Althaqafi MK; AlQurashi W; Bader BA; Mohanna AT; Almahdi B
Cureus; 2022 Feb; 14(2):e22414. PubMed ID: 35371700
[TBL] [Abstract][Full Text] [Related]
5. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
[TBL] [Abstract][Full Text] [Related]
6. A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination.
Daines B; Madigan LM; Vitale PA; Khalighi M; Innes M
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259862
[TBL] [Abstract][Full Text] [Related]
7. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption.
Anderson HJ; Lee JB
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577848
[TBL] [Abstract][Full Text] [Related]
8. Generalized fixed drug eruption following Pfizer-BioNtech COVID-19 vaccination.
Kabir S; Feit EJ; Heilman ER
Clin Case Rep; 2022 Dec; 10(12):e6684. PubMed ID: 36514459
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of COVID-19 and COVID-19 vaccination.
Nakashima C; Kato M; Otsuka A
J Dermatol; 2023 Mar; 50(3):280-289. PubMed ID: 36636825
[TBL] [Abstract][Full Text] [Related]
11. Generalized bullous fixed drug eruption treated with cyclosporine.
Malviya N; Cyrus N; Vandergriff T; Mauskar M
Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329494
[TBL] [Abstract][Full Text] [Related]
12. Bullous Pemphigoid Developed after the COVID-19 Vaccine.
Linares-Navarro R; Ramírez GR; Perandones-González H; Rodríguez-Prieto MÁ
Skinmed; 2023; 21(3):200-202. PubMed ID: 37634107
[TBL] [Abstract][Full Text] [Related]
13. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
Johnston MS; Galan A; Watsky KL; Little AJ
JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination.
Larson V; Seidenberg R; Caplan A; Brinster NK; Meehan SA; Kim RH
J Cutan Pathol; 2022 Jan; 49(1):34-41. PubMed ID: 34292611
[TBL] [Abstract][Full Text] [Related]
15. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review.
Mitre V; Applebaum DS; Albahrani Y; Hsu S
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469697
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
17. A nonscarring sublamina densa bullous drug eruption.
Roholt NS; Lapiere JC; Traczyk T; Chan LS; Woodley DT
J Am Acad Dermatol; 1995 Feb; 32(2 Pt 2):367-71. PubMed ID: 7829742
[TBL] [Abstract][Full Text] [Related]
18. Side effects after COVID-19 vaccinations among residents of Poland.
Andrzejczak-Grządko S; Czudy Z; Donderska M
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
[TBL] [Abstract][Full Text] [Related]
19. Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
Perron E; Viarnaud A; Marciano L; Karkouche R; Wechsler J; De Prost N; Chosidow O; Wolkenstein P; Ingen-Housz-Oro S; Ortonne N
Eur J Dermatol; 2021 Jun; 31(3):372-380. PubMed ID: 34309522
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
